Amylyx Pharmaceuticals Inc
AMLX7.935USD
+0.220+2.85%
交易中 （美东）报价延迟15分钟
706.86M总市值
亏损市盈率 TTM
关于 Amylyx Pharmaceuticals Inc 公司
Amylyx Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司致力于发现和开发神经退行性疾病的治疗方法。该公司专注于其候选产品的开发和商业化：用于治疗 Wolfram 综合征和进行性核上性麻痹的 AMX0035，以及该公司用于治疗肌萎缩侧索硬化症 (ALS) 的靶向钙蛋白酶-2 的反义寡核苷酸 AMX0114。AMX0035 是一种双未折叠蛋白反应 (UPR)-Bax 凋亡抑制剂，由 PB 和 TURSO（也称为 TUDCA）组成。该公司的 Avexitide 是一种在研的、一流的胰高血糖素样肽 1 (GLP-1) 受体拮抗剂，已在五项临床试验中针对减肥后低血糖症 (PBH) 进行了评估，并且还针对先天性高胰岛素血症 (HI) 进行了研究，这两种疾病的特征都是高胰岛素血症性低血糖。
公司简介
公司代码AMLX
公司名称Amylyx Pharmaceuticals Inc
上市日期Jan 07, 2022
CEOMr. Justin Klee
员工数量123
证券类型Ordinary Share
年结日Jan 07
公司地址43 Thorndike Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02141
电话16176820917
网址https://www.amylyx.com/
公司代码AMLX
上市日期Jan 07, 2022
CEOMr. Justin Klee
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
收入明细
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
87.37M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月25日 周五
更新时间: 7月25日 周五
持股股东
股东类型
持股股东
持股股东
占比
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
持股股东
持股股东
占比
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
股东类型
持股股东
占比
Hedge Fund
37.33%
Investment Advisor
25.77%
Individual Investor
9.53%
Private Equity
9.22%
Investment Advisor/Hedge Fund
6.10%
Research Firm
3.54%
Venture Capital
2.72%
Pension Fund
0.22%
Sovereign Wealth Fund
0.13%
Other
5.44%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
402
86.90M
97.48%
-7.80M
2025Q1
421
95.29M
107.20%
-3.35M
2024Q4
427
70.75M
84.73%
-29.75M
2024Q3
419
63.91M
89.33%
-37.09M
2024Q2
415
63.87M
89.96%
-35.05M
2024Q1
393
69.90M
101.03%
-23.62M
2023Q4
373
76.45M
112.48%
-12.85M
2023Q3
341
74.63M
110.02%
-3.94M
2023Q2
310
76.31M
113.70%
-2.01M
2023Q1
276
73.14M
110.85%
-1.57M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Perceptive Advisors LLC
7.87M
8.83%
+1.10M
+16.24%
Mar 31, 2025
TCG Crossover Management, LLC
5.94M
6.67%
+1.30M
+27.99%
Mar 31, 2025
Adage Capital Management, L.P.
5.70M
6.39%
+5.70M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.12M
4.62%
+1.42M
+52.89%
Mar 31, 2025
Klee (Justin B)
3.36M
3.76%
+235.72K
+7.56%
Apr 11, 2025
Cohen (Joshua Barry)
3.36M
3.76%
+299.42K
+9.80%
Apr 11, 2025
Millennium Management LLC
3.08M
3.46%
+2.49M
+418.62%
Mar 31, 2025
Nantahala Capital Management, LLC
2.93M
3.29%
+1.48M
+102.07%
Mar 31, 2025
Citadel Advisors LLC
2.76M
3.09%
+787.07K
+39.94%
Mar 31, 2025
Saturn V Capital Management LP
2.43M
2.72%
+1.54M
+172.92%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
0.44%
Federated Hermes MDT Small Cap Core ETF
0.22%
iShares Micro-Cap ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
查看更多
iShares Neuroscience and Healthcare ETF
占比1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.44%
Federated Hermes MDT Small Cap Core ETF
占比0.22%
iShares Micro-Cap ETF
占比0.1%
Invesco Nasdaq Biotechnology ETF
占比0.06%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Avantis US Small Cap Equity ETF
占比0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.04%
iShares Biotechnology ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
